Vertex Pharmaceuticals Incorporated: Vertex Announces US FDA Approval for Expanded Use of CASGEVY for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia
Source Summary
- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia - - Approximately 5,500 additional ch...
Advertisement